Pioneering Ebola Vaccine Research


HJFMRI supported early testing of Ebola vaccine candidates, leveraging its established network of clinical research sites in Africa to pivot towards Ebola countermeasures.

The HJFMRI research network supports the Walter Reed Army Institute of Research (WRAIR), which has completed eight clinical trials of five different investigative Ebola virus vaccine candidates, more than any single institution in the world. 

Working with WRAIR, HJF helped support the first Ebola vaccine clinical trial in Africa in 2009, and in 2015 HJFMRI scientists and infrastructure helped conduct the first Ebola vaccine study in Nigeria, a Phase 2 trial of the ChAd3 vaccine. 

In 2016 HJFMRI supported WRAIR to implement a multi-site Phase 1/2a Ebola vaccine trial of the Ad26.ZEBOV and MVA-BN-Filo vaccine regimen with partners in Africa. The study strengthened the safety and immunogenicity evidence of the regimens in healthy subjects and extended the population studied in Phase 1 to include volunteers up to and including 70 years of age and volunteers with stably suppressed HIV-infection.